March 24, 2025

Pragmatic Accelerated Theta-Burst Stimulation Shows Promise for Treatment-Resistant Depression

Written by Joao L. de Quevedo, MD, PhD Introduction Major depressive disorder (MDD) affects millions worldwide, and for nearly half of these individuals, standard treatments such as medication and psychotherapy are insufficient. This condition, known as treatment-resistant depression (TRD), has prompted…


March 17, 2025

rTMS vs. Antidepressants: A New Path for Treatment-Resistant Depression

Written by Joao L. de Quevedo, MD, PhD Introduction For individuals with treatment-resistant depression (TRD)—those who have not found relief with traditional antidepressants—the search for effective treatment options can be frustrating and exhausting. A recent randomized controlled trial by Dalhuisen et…


March 10, 2025

Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression

Written by Joao L. de Quevedo, MD, PhD Introduction Depression is a devastating illness, but for those with treatment-resistant depression (TRD)—a form of depression that does not respond to multiple treatment attempts—finding relief can feel nearly impossible. Traditional antidepressants, therapy, and…


March 3, 2025

Electroconvulsive Therapy (ECT) might be a Lifesaving Treatment Option for Bipolar Disorder.

Written by Joao L. de Quevedo, MD, PhD Introduction Electroconvulsive therapy (ECT) has been a subject of both fascination and controversy for decades. Often misunderstood due to its portrayal in popular media, ECT remains one of the most effective treatments for…


February 24, 2025

Key Insights from a Landmark Study Exploring Vagus Nerve Stimulation for Treatment-Resistant Depression

Written by Joao L. de Quevedo, MD, PhD Introduction Treatment-resistant depression (TRD) remains one of the most challenging conditions in psychiatry. With limited options for patients who do not respond to conventional treatments, researchers continue to explore novel interventions. One such…


February 17, 2025

How Long Should Antipsychotics Be Used After a Manic Episode? Insights from a Key Study

Written by Joao L. de Quevedo, MD, PhD For individuals with bipolar I disorder, preventing relapse after a manic episode is a crucial part of long-term treatment. Atypical antipsychotics like risperidone and olanzapine are often prescribed alongside mood stabilizers such…


February 10, 2025

Electroconvulsive Therapy (ECT) for Children and Adolescents

Written by Joao L. de Quevedo, MD, PhD Electroconvulsive therapy (ECT) has long been a topic of debate in mental health treatment, especially when it comes to its use in children and adolescents. While often associated with adults who have severe…


February 3, 2025

Unlocking the Genetics Behind Treatment-Resistant Depression

Written by Joao L. de Quevedo, MD, PhD Treatment-resistant depression (TRD) represents one of the most complex challenges in mental health care, affecting millions of individuals worldwide who fail to respond to conventional antidepressants. A recent review, led by Chiara Fabbri…


January 27, 2025

Understanding the Neurobiology of Treatment-Resistant Depression

Written by Joao L. de Quevedo, MD, PhD Treatment-resistant depression (TRD) presents a unique challenge in mental health care, affecting approximately 20-30% of individuals with major depressive disorder (MDD). Unlike typical depression, TRD is characterized by a lack of response to…


January 22, 2025

FDA Expands Approval of Intranasal Esketamine Therapy (Spravato)

Written by Joao L. de Quevedo, MD, PhD In a significant step forward for mental health care, the U.S. Food and Drug Administration (FDA) has expanded its approval of Spravato (esketamine) nasal spray. Initially approved in 2019 for treatment-resistant depression,…


Pages